Shire Beats, Updates Outlook - Analyst Blog Benzinga We note that Shire's attention deficit hyperactivity disorder (ADHD) franchise is transforming from Adderall XR to Vyvanse, with Vyvanse second quarter ... and more »

Shire Beats, Updates Outlook Zacks.com We note that Shire's attention deficit hyperactivity disorder (ADHD) franchise is transforming from Adderall XR to Vyvanse, with Vyvanse second quarter ... and more »

Shire offers 428 million euros to buy Movetis Pharma Times ... on its attention-deficit hyperactivity disorder franchise, headed by Vyvanse (lisdexamfetamine) and the off-patent Adderall XR (mixed amphetamine salts).

Shire, the British drugmaker buying Belgium's Movetis , beat second-quarter expectations as its rare disease franchise capitalised on production troubles at United States rival Genzyme. (05/08/2010 09:12:08) Shire the acquisitive drugmaker buying Belgium's Movetis beat second-quarter expectations after its rare disease franchise capitalised on production woes at U.S. rival Genzyme .